Samuel Blackman

Sam Blackman, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology and has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, where he led the advancement of a novel immunotherapeutic toward Phase 1 clinical trials. Prior to Mavupharma, he was Head of Clinical Development at Silverback Therapeutics. Prior to Silverback, Dr. Blackman held roles of increasing responsibility at Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial”. Through roles at CureSearch for Children’s Cancer, and ACCELERATE, Dr. Blackman is an active leader in the pediatric oncology drug development community.

Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and Ph.D. degrees from the University of Illinois at Chicago, and his undergraduate degree in Philosophy from the University of Chicago.